Straits Times Index
3,343.93 +13.12 (+0.39%) Nikkei
38,659.17 -44.34 (-0.11%) Hang Seng
18,391.79 -85.01 (-0.46%) FTSE 100
8,285.34 +38.39 (+0.47%) Bitcoin USD
71,131.72 +127.59 (+0.18%) CMC Crypto 200
1,478.83 -45.97 (-3.01%)
MYGN Nov 2024 18.000 call
| Previous close | 4.9000 |
| Open | N/A |
| Bid | 3.6000 |
| Ask | 4.2000 |
| Strike | 18.00 |
| Expiry date | 2024-11-15 |
| Day's range | 4.9000 - 4.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksMyriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GuruFocus.comInsider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN)
On June 4, 2024, Daniel Spiegelman, Director at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 7,576 shares of the company.
GlobeNewswireMyriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. The conditions added to the Universal Plus panel were named in the American College of Medical Genetics and Genomics (ACMG) practice resource for carrier screen
